INTRODUCTION
Despite their well characterized role in development, functions of homeobox transcription factors in the adult brain still remain elusive. For example, members of the paired-type homeobox (Pax) transcription factor family are expressed in specific neurons in the midbrain and the olfactory bulb (Stoykova and Gruss, 1994) , but neither their targets nor the physiological role of this late expression is known. As almost all Pax transcription factors act as fate determinants during development (Osumi et al., 2008) , it is possible that they function similarly in adulthood to maintain neuronal identity. Alternatively, Pax transcription factors expressed in mature neurons may regulate novel targets important for specification or regulation of neuronal function and activity. Finally, it is conceivable that Pax transcription factors regulate pathways involved in neuronal survival. Indeed, it is puzzling that specific types of neurons succumb to neurodegeneration, despite the rather widespread expression of the genes affected by the disease-causing mutations (Alavian et al., 2008; Friedlander, 2003; Zhao et al., 2008) . Thus, neuronal subtype-specific expression of regulatory transcription factors may contribute to selective cell death.
Here, we examined the role of Pax6 in mature dopaminergic neurons of the olfactory bulb (OB) in mice. Pax6 is expressed in stem and progenitor cells in some regions of the developing CNS during neurogenesis (Ericson et al., 1997; Heins et al., 2002; Kohwi et al., 2005; Stoykova and Gruss, 1994; Stoykova et al., 2000) but only in very few neuronal subpopulations in the adult brain, such as the dopaminergic neurons in the glomerular layer of the OB, granule neurons in the cerebellum, and amacrine and ganglion cells of the retina (Stoykova and Gruss, 1994) . Pax6 expression in progenitors ceases at early postnatal stages and persists only in progenitors in the adult neurogenic regions (Brill et al., 2009; Hack et al., 2005; Kohwi et al., 2005; Stoykova and Gruss, 1994) . Pax6 acts proneurogenic in adult neural progenitors (Hack et al., 2005) , similar to its role during development (Heins et al., 2002) , but also plays a role to specify neuronal subtype identity in the adult and developing brain (Hack et al., 2005; Kohwi et al., 2005; Kroll and O'Leary, 2005; Nikoletopoulou et al., 2007; Stoykova et al., 2000; Tuoc et al., 2009 ). Pax6 cooperates with Dlx2 in adult neuroblasts to specify the dopaminergic identity of periglomerular neurons (PGNs) in the olfactory bulb (Brill et al., 2008; Hack et al., 2005) . As only these dopaminergic neurons continue to express Pax6 lifelong, it is also conceivable that Pax6 may be further required to maintain this neuronal subtype identity. Interestingly, the dopamine levels are subject to activity dependant regulation in PGNs (Bastien-Dionne et al., 2010) .
Here, we used genetic ablation of Pax6 exclusively in mature dopaminergic neurons and found that Pax6 is essential to inhibit programmed cell death of these neurons by controlling the expression of CryaA which prevents activation of procaspase-3. These data reveal a pathway of transcriptional regulation of neuronal survival in a highly subtype-specific manner in the adult brain.
RESULTS

Pax6 Is Necessary for Survival of Dopaminergic PGNs
Periglomerular neurons (PGNs) represent a heterogeneous population of both excitatory and inhibitory interneurons in the olfactory bulb (Figures 1A and 1B; Brill et al., 2009; Kosaka et al., 1988; Kosaka and Kosaka, 2007; Nakamura et al., 2005) . A subpopulation of about 20% of the inhibitory PGNs employs the transmitter dopamine and expresses the transcription factor Pax6 ( Figure 1C ). Consistent with previous data (Hack et al., 2005) , we found that Figure S1 .
virtually all dopaminergic PGNs identified as immunoreactive to the dopamine transporter (DAT), which is expressed only in fully mature dopaminergic neurons several weeks after their birth (Revay et al., 1996) , are also Pax6 immunoreactive (91% ± 3%, n[animals] = 11, at least 1000 cells per animal analyzed). Similarly neurons expressing tyrosine hydroxylase (TH), the rate-limiting enzyme for dopamine biosynthesis, in the glomerular layer are positive for Pax6 ( Figure 1C) . To address the function of Pax6 in these fully mature postmitotic neurons we genetically ablated Pax6 by Cre-Lox recombination in mice with Cre expressed from the DAT locus (DAT::Cre [Zhuang et al., 2005] ) and exons 4-6 of the Pax6 gene flanked by loxP sites (Pax6 fl/fl ) (Ashery-Padan et al., 2000) . Since Pax6 is not expressed in any other dopaminergic neuron population in the brain (Stoykova and Gruss, 1994) , this allowed us to specifically examine the role of Pax6 in dopaminergic OB interneurons. Recombination mediated by DAT::Cre and indicated by a GFP reporter (Novak et al., 2000) was specific to mature DAT-expressing neurons (no DAT-negative cells were recombined and GFP + [see Figures S1A and S1B available online]) and efficient (70% ± 6% of all DAT + PGNs were GFP + ; 5 animals; 450 cells analyzed per animal; Figures S1A and S1B). Notably, however, we also observed a small fraction of calretinin + PGNs expressing DAT and hence also being
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The Role of Pax6 and CryaA in Postmitotic Neurons recombined by DAT::Cre ( Figure S1F ), while no overlap was found with calbindin + PGNs ( Figure S1H ).
We were surprised to see that Cre + cells in 2-month-old DAT::
Cre//Pax6 fl/fl mice were still Pax6 immunoreactive ( Figure S1E ). To examine whether this is due to a failure to recombine the Pax6 floxed alleles or to stability of the (Brill et al., 2008; Hack et al., 2005 Figure 1D ), suggesting that the dopaminergic neurons may succumb to cell death rather than acquire a different fate. This loss of dopaminergic PGNs was not due to unspecific effects of expressing high levels of Cre or GFP in dopaminergic neurons, as DAT::Cre//GFP + neurons did not die in the OB of heterozygous floxed mice nor in the midbrain where Pax6 is not expressed in the dopaminergic neurons (data not shown). Therefore, these data suggest that loss of Pax6 affects specifically the survival of mature dopaminergic PGNs. To elucidate the mechanism by which Pax6-deficient neurons die, we stained dissociated cells of the adult OB for propidium iodide (PI) and annexinV (Casciola-Rosen et al., 1996) to discriminate live (annexinV-negative, PI-negative), early apoptotic (annexinV-positive, PI-negative) and necrotic/late apoptotic (annexinV-positive, PI-positive) cells (Figures 2A and 2B ). Reporterpositive ( Figure 2C ), Pax6 fl/fl cells from the OB of 3.5 month old mice contained significantly (p < 0.01) more early apoptotic cells (21.1% ± 1.5%; 3 animals, 10,000 events per animal) than cells from the OB of their heterozygous siblings (13.2% ± 1.0%; 3 animals, 10000 events per animal) ( Figures 2D and 2E ) that did not differ from WT animals (data not shown). Among adult generated neuroblasts that newly arrive in the OB, about 50% succumb to cell death and the remainder incorporate into the neuronal network (Petreanu and Alvarez-Buylla, 2002 Figure 2F ), the time when Pax6 immunoreactivity is lost in the OB dopaminergic neurons ( Figure S1E ).
Loss of CryaA Expression Causes Neuronal Death upon Pax6 Depletion
To further elucidate the role of Pax6 in preventing programmed cell death (PCD) in dopaminergic PGNs, we examined the pathways that commit dopaminergic PGNs to the PCD in the absence of Pax6 function. p75 and galectin have been implicated in regulating neuronal cell death (Nikoletopoulou et al., 2007; Plachta et al., 2007) , including the death of misspecified neurons in the embryonic cortex and midbrain (Alavian et al., 2009; Nikoletopoulou et al., 2007; Plachta et al., 2007) . We examined p75 and galectin in the adult OB upon loss of Pax6. The number of cells immunoreactive for p75 and galectin ( Figures S2A-S2C and data not shown) and the mRNA expression levels of p75 ( Figure S2D ) among the reporter positive cells isolated by FACS did not differ between the genotypes. As this analysis was carried out at the stage when the annexinV + fraction of dopaminergic OB neurons was increased (3.5-month-old mice; Figures 2D and 2E ), we concluded that p75 and galectin are not altered and not responsible for the death of dopaminergic PGNs devoid of Pax6. Next, we examined the crystallin gene family (Lanneau et al., 2008) since its members are well-known targets of Pax6 in the lens (Cvekl and Duncan, 2007) and also regulate cell survival (Morozov and Wawrousek, 2006) . Among the crystallins, aBand bB2-crystallin have been reported to be expressed in the brain (Graw, 2009) . However, in neurons of the OB including dopaminergic PGNs, we surprisingly detected crystallin aA (CryaA), which had not yet been reported to be expressed in the brain (Graw, 2009; Figures 3A, 3B, and S3) . Interestingly, CryaA expression was confined to the mature neurons immunoreactive to the panneuronal marker NeuN (Figures S3C-S3E Figures 3B and 3C ), demonstrating a specific loss of CryaA in the Pax6-deficient neurons. These data raised the possibility that the reduced levels of CryaA may be causative for the death of dopaminergic PGNs after loss of Pax6.
To test this hypothesis, we transduced adult neuronal progenitors in the RMS of 2.5-month-old mice with lentiviruses encoding for CryaA-specific shRNA 5 (Figures 3E, S4A, and S4B) or for a control shRNA ( Figure 3D ). Both virus constructs expressed GFP from an independent promoter to identify transduced cells. As CryaA shRNA 5 efficiently knocks down CryaA ( Figures S4A  and S4B ), we depleted CryaA from all adult-generated OB neurons. Despite CryaA knockdown, neuronal differentiation was not changed 8 weeks after viral vector injection, and we could not observe any differences in the distribution of GFP-positive cells in the OB between control and CryaA shRNA transduced cells ( Figure 3F ). However, when we analyzed the proportion of transduced cells with dopaminergic identity 8 weeks after the viral transduction, we observed a significant decrease (p < 0.005) in DAT + cells among transduced cells to 25% of the proportion observed in the control shRNA transduced cells ( Figure 3F ). Thus, CryaA is specifically required for the survival of dopaminergic, but not of all adult generated OB interneurons.
To test whether CryaA is sufficient to maintain dopaminergic neurons even in the absence of Pax6, we examined whether CryaA expression rescues Pax6-deficient dopaminergic PGNs from apoptosis. We infected adult neuronal progenitors migrating in the rostral migratory stream toward the OB with a MLV-based retroviral vector encoding for CryaA and dsRed or a control vector containing dsRed only ( Figures 3G and 3H ). Thereby we target all adult generated neuroblasts with a permanent, Pax6-independent expression of CryaA. To allow sufficient differentiation time and to examine whether migration and differentiation occurs normally despite the overexpression of CryaA, we examined the OBs 2 months after viral vector injection into the RMS of 2. Figure 3H ). These dopaminergic neurons also expressed DAT::Cre and were GFP + ( Figures 3D-3F ). The proportion of dopaminergic neurons labeled by GFP (in green) among the virally transduced cells expressing dsRed (in red) in DAT::Cre//GFP//Pax6 fl/+ mice was similar to previous analyses (Brill et al., 2008; Hack et al., 2005) and did not differ between virus expressing CryaA and control virus expressing only dsRed ( Figure 3I ). These data indicate that overexpression of CryaA This method is based on the difference in integrity of the plasma membrane in apoptosis and necrosis. One of the earliest features of apoptotic cells is the translocation of the phospholipid phosphatidylserine (PS) from the inner to the outer leaflet of the plasma membrane. Therefore, early apoptotic cells can be efficiently labeled with annexinV, which has a high affinity to PS. Loss of plasma membrane integrity, characterizing both necrosis and the late phase of apoptosis, allows passage of propidium iodide (PI) through the plasma membrane and labeling of DNA. Assessing recombined, reporter positive cells (P2) To determine whether CryaA re-expression in Pax6-deficient dopaminergic PGNs rescues their numbers due to improved survival, we analyzed the proportion of dying cells using the annexinV-based assay in DAT::Cre//GFP//Pax6 fl/fl animals with or without CryaA-mediated rescue by FACS. We observed a 2-fold decrease in the proportion of dying cells after retroviral vector expression of CryaA compared to the control vector ( Figure 3J ; cells double-positive for dsRed and GFP). Importantly, the overexpression of CryaA did not affect the survival of nondopaminergic cells that had a similar rate of 10% cell death in both CryaA and control virus-transduced cells ( Figure 3J ; dsRed only cells) in agreement with no change in the number of nondopaminergic cells upon retroviral expression of CryaA ( Figures 3G-3I ). Taken together, CryaA does not alter the fate and the specification of PGN but prevents PCD of dopaminergic PGNs downstream of Pax6. See also Figure S3 .
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CryaA Prevents Activation of Caspase-3 We performed shRNA mediated knockdown of CryaA in the P19 cell line grown under both undifferentiated and differentiated conditions (see Experimental Procedures). P19 cells express Pax6 and CryaA in both conditions investigated (Figures S4B and S5C) and the CryaA protein can be efficiently depleted from these cells by CryaA-specific shRNA5 expression as described above ( Figures S4A and S4B ). Supporting the idea that a reduction of CryaA results in apoptosis, shRNA5-mediated CryaA knockdown in P19 cells resulted in reduced numbers of CryaA-shRNA5-transfected cells compared to the control shRNAs ( Figures 4A-4C ) by 30 hr after the transfection. CryaA shRNA5-expressing cells display cell rounding, pyknotic nuclei and nuclear fragmentation (Figure 4 and data not shown), the typical hallmarks of cells undergoing PCD (Boldyrev, 2000) . Significantly increased fractions of early apoptotic and late apoptotic/ necrotic cells preceded the reduction in the number of CryaA-shRNA5 transduced cells, as revealed by PI and annexinV staining 24 hr after transduction ( Figure 4E ). As the activation of caspase-3 is the key event in the commitment of cells to PCD (Conradt, 2009) , we examined caspase-3 protein following CryaA knockdown. When protein extract from control or CryaA-shRNA5 transduced P19 cells was probed with an anti-caspase antibody recognizing both active (13 and 17 kDa) and pro-form (39 kDa), only cells exposed to CryaA knockdown showed activated caspase-3 ( Figure 4F ). Conversely, these bands were undetectable after control transfection or in the protein extracts of nontransfected cells ( Figure 4F ). Consistent with a role of caspase-3 activation in mediating the CryaA knockdown triggered apoptosis, treatment of CryaA shRNA5-transfected cells with the caspase inhibitor ZVAD-fmk fully abolished cell death ( Figure 4D ). As activation of caspase-3 has also been implicated in cellular functions other than PCD, such as neuronal differentiation (Chen et al., 1998) , we performed time-lapse imaging (Costa et al., 2008; Eilken et al., 2009 ) to further examine the role of CryaA. Although 90% of the progeny of CryaAspecific shRNA5 transfected cells died within 35 hr of observation ( Figures S4C and S4D ), CryaA knockdown did not interfere with cell cycle length or the mode of division of P19 cells grown in undifferentiated conditions ( Figure S4E ), compatible with our in vivo results showing no influence on proliferation, migration and cell fate after viral vector-mediated knockdown or overexpression in vivo. Taken together, these data identify CryaA as a key regulator of the apoptotic pathway in neurons. See also Figure S4 .
Pax6 Homeodomain Controls CryaA Expression
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The Role of Pax6 and CryaA in Postmitotic Neurons the RED subdomains and the paired-type homeodomain (HD; Figure 5A ). Alternative splicing (Epstein et al., 1994) or different transcription initiation (Glaser et al., 1992) generate mainly three Pax6 forms, the canonical Pax6 containing all three DNA-binding motifs, the Pax6(5a) form in which binding of the PAI domain to DNA is abolished and the PDless form that lacks the entire paired domain (PD-less) and can bind DNA only via its homeodomain ( Figure 5A ; see also Haubst et al., 2004) . To test whether any of these Pax6 proteins would regulate CryaA we examined transcriptional activation of the 2.1 kb CryaA promoter (Yang et al., 2006) in luciferase assays performed in N2A and P19 cells ( Figures 5A and 5B ). Consistent with previous data obtained with lens cells (Yang et al., 2006) , transduction of Pax6 forms containing the PD and HD (canonical and 5a) led to a significant increase in CryaA promoter mediated luciferase expression ( Figure 5B ). In contrast to the data obtained with lens cells, we also observed activation by the PDless protein ( Figures 5A and 5B). DNA binding of this HD is essential for activation of the CryaA promoter as a point mutation abolishing DNA binding of the HD (
) (Favor et al., 2001 ) also abolished the activation of this promoter ( Figure 5B ). Taken together, these data suggest that Pax6 directly regulates CryaA expression by DNA binding of the HD.
We next examined the expression of the different forms of Pax6 in the OB in vivo and found expression of the PDless form, which was virtually absent in the subependymal zone, where adult neural progenitor cells and neuroblasts express Pax6 (Brill et al., 2008; Hack et al., 2005) . In contrast, canonical Figure S4 ]) from total lysates of the adult OB. No signal for Pax6 forms was detected in the wash fraction or immunoprecipitates using IgG control, whereas signals for both canonical (black arrow) and PDless Pax6 (red arrow) forms were detected after both EtBr and benzonase treatment indicated direct protein-protein interaction in the adult OB between full length Pax6 and PD-less. (H and I) Histograms depicting Pax6 (H) and H3 K9ac (I) distribution at the mouse aA-crystallin gene locus in OB chromatin. The numbers on x axis represent the primer position in CryaA locus (Yang et al., 2006) . The red line indicates median background signal averaged through the CryaA locus. The relative enrichment (RE) unit represents 10% of the input. *p < 0.05; ***p < 0.001 and brackets in (B), (C), (F), (H), and (I) are SEM. See also Figure S5 .
Pax6 form was present in both SEZ and OB ( Figures 5C, 5D , and S6J). These data suggest the intriguing concept that mature neurons expressing Pax6 in the OB specifically upregulate the PD-less form of Pax6.
Given the coexistence of canonical and PD-less forms of Pax6 in vivo ( Figures 5C and 5D) , we further tested the influence of endogenous Pax6 expressed in P19 cells ( Figure S5 ) by using a cell line lacking endogenous Pax6 expression, HEK293T. When we transduced these cells with the canonical or PD-less form of Pax6, no activation of the CryaA promoter was observed ( Figure 5F ) in striking contrast to the results obtained in the cell line with endogenous Pax6 levels ( Figure 5B ). However, cotransduction of the canonical and PD-less form of Pax6 resulted in very strong transcriptional activation of the CryaA promoter ( Figure 5F ), demonstrating the necessity of these forms to interact. This potent activation was fully abolished by cotransduction of the canonical Pax6 with the PD-less homeodomain mutant (PD-less Pax6 4Neu ) ( Figure 5F ). These results show that CryaA transcription depends exclusively on the DNA binding activity of the Pax6 HD of the PDless protein, since it cannot be compensated by the nonmutant HD of the canonical Pax6, and requires interaction of the PD-less form with the canonical form of Pax6.
To examine whether the requirement for both the full length and PD-less form of Pax6 depends on a physical interaction of the two proteins, we performed coimmunoprecipitation experiments in protein extracts from the adult OB. To do so we took advantage of an N-terminal Pax6 antibody that does not recognize the PD-less protein lacking the N terminus (Figures S4F and S4G) . Precipitation with this antibody should therefore precipitate only Pax6 forms containing a PD (either canonical or 5a). The immunoprecipitates were then probed with a C-terminal Pax6 antibody recognizing all Pax6 forms ( Figure S4F ). We observed the PDless protein in Western blots (red arrowhead in Figure 5G ). As these experiments were performed after treatment with ethidium bromide or benzonase blocking protein DNA interactions, the data suggest a direct protein-protein interaction between the full length and PDless Pax6 proteins ( Figure 5G ). Taken together with the data obtained in the luciferase experiments, we conclude that CryaA expression is regulated by HD-mediated DNA binding of a complex consisting of the Pax6 full length and PD-less protein. To demonstrate that Pax6 interacts with the CryaA locus in vivo, we isolated chromatin from OBs of 3-month-old animals and performed a series of qChIP analyses ( Figure 5H ). The enrichment of Pax6 was found in the CryaA promoter region (regions À500 and À250 bp; Figure 3H ). In addition, the À500 bp promoter region showed increased signals corresponding to H3 K9 acetylated histones ( Figure 3I ), a mark localized to the 5 0 regions of transcriptionally active genes (Liang et al., 2004) . Taken together, these data suggest that Pax6 directly regulates CryaA expression through association with the upstream promoter regions in chromatin of OB cells.
Paired-Type Homeodomain Dysfunction Impairs Survival of Dopaminergic PGNs
The above experiments suggested a critical role of the HD in regulating CryaA expression and hence dopaminergic PGN survival. We tested this in vivo in a mouse line harboring a point mutation in the Pax6 HD abolishing DNA binding, the Pax6 (further named Pax6 14Neu ) mice . In contrast to most Pax6 mutants Graw et al., 2005; Haubst et al., 2004) , Pax6 14Neu is not homozygous lethal. Consistent with normal forebrain development in Pax6 mutants with a defective HD (Haubst et al., 2004) , adult mice homozygous for the Pax6 14Neu allele also do not show gross morphological changes in the forebrain (Figures S6A-S6C ). This allowed us to further study both neurogenesis and survival of dopaminergic neurons in these animals. First, we examined the presence and number of adult neural stem cells in the subependymal zone of Pax6 14Neu mice by the neurosphere assay. The number of neurospheres generated, their size and their self-renewing capacity did not differ in Pax6 14Neu mice compared to their WT siblings ( Figures   S6D-S6F ). Moreover, neurospheres from the Pax 14Neu mutants were tripotent and not different from WT cells in regard to the proportion of neurons, oligodendrocytes and astrocytes generated 7 days after withdrawal of growth factors ( Figures  S6G-S6H ).
As the full length form of Pax6 was previously implicated in adult neurogenesis (Hack et al., 2005; Kohwi et al., 2005) , we examined neuroblasts in sections by immunostaining for doublecortin (DCX) and by FACS using live staining for PSA-NCAM. Neuroblasts were present in equal numbers and locations in the Pax6 14Neu/14Neu mutants and their heterozygote or WT littermates in both read-outs ( Figure S6I and data not shown). As the proportion of PSA-NCAM-positive was quantified in the OB, we can further conclude that an equal number of young neurons arrive to the OB of Pax6 14Neu/14Neu animals as in their WT siblings ( Figure S6I ), demonstrating that neurogenesis and neuronal migration are normal in these mutant mice. This is in full agreement with previous work demonstrating that the DNA-binding mutations of the HD of Pax6 do not affect proliferation, neurogenesis, and neuronal migration during development (Haubst et al., 2004) . However, when we examined the composition of PGNs in the glomerular layer of 3.5-month-old Pax6 14Neu/14Neu mice, we observed a significant reduction of DAT + PGNs to 20% of that of control mice ( Figures 6B and 6G ). All other PGN subtypes were unaffected ( Figures 6C-6G ). To examine whether this was due to a failure of DAT + neurons to be generated or to survive, we applied BrdU to label recently generated dopaminergic neurons. The recently (4-6 weeks before) generated DAT + neurons comprise only 10% ± 3% of all DAT + PGNs in control mice (3 animals examined and at least 500 cells counted per genotype). In contrast, the vast majority of the few DAT + neurons present in the OB of homozygous Pax6 14Neu mice were all recently generated (80% ± 5% BrdU + ), suggesting that in Pax6 14Neu mice DAT + neurons are generated but quickly lost. Taken together, these data strongly suggest that survival of dopaminergic PGNs is severely compromised in Pax6 14Neu/14Neu mice.
Consistent with the evidence presented above that the HD of Pax6 is essential to regulate CryaA, we detected a significant reduction in the density of CryaA + cells in the Pax6
selectively in the glomerular layer ( Figure 6H ) which was due to a strong reduction in the number of DAT and CryaA double-positive cells ( Figure 6I ; p < 0.05, 5 animals per genotype analyzed) compared to their WT or heterozygous siblings. Thus, these data are consistent with the concept that the DNA-binding mutation in the HD of Pax6 14Neu causes a downregulation of CryaA in dopaminergic PGNs which results in death of this population. Importantly, no changes in mRNA of either PD or HD containing forms of Pax6 as measured by qPCR were detectable in E14 cortices and adult OBs of Pax6 14Neu/14Neu mutants and their age-matched Pax6 14Neu/+ siblings ( Figure S6K and data not shown), supporting the concept that the loss of DAT + PGNs via loss of CryaA is indeed due to the point mutation in the HD rather than alterations in the overall expression levels of Pax6 that are observed in the full Pax6 mutants and can cause cell death (Holm et al., 2007; Tuoc and Stoykova, 2008) .
DISCUSSION
Here, we revealed a function of Pax6 in regulating the survival of specific neuron subtypes in the adult brain. We demonstrated that this function is achieved by utilizing a different DNA-binding domain as used in the developmental functions of Pax6 and is exerted by the regulation of CryaA. CryaA is required to prevent the activation of the caspase cascade and thereby inhibits progression of the dopaminergic OB interneurons to PCD in the adult mouse brain. These results thereby demonstrate a pathway to regulate neuron survival in the adult brain in a subtype-specific manner.
Neuron Survival in the Adult Brain During development, especially of the peripheral nervous system, PCD is part of the program sculpturing neuron numbers and thereby neuronal connectivity (Dicou and Perez-Polo, 2009 ). PCD is actively inhibited by external survival cues (Chang and Johnson, 2002) or cell intrinsic mechanisms (Hatzold and Conradt, 2008) regulating different signaling cascades to inhibit the activation of procaspase-3 and thereby promoting the survival of the correct cell types in appropriate numbers (for review see Conradt (2009) .
In contrast, little is known about the regulation of neuronal survival in the normal, uninjured adult brain. The number of neurons in most regions of the adult brain is constant and virtually no neuronal cell death occurs. However, in the regions of the adult brain where neurogenesis continues also PCD continues and only about half of all newly arriving neuroblasts survive (Petreanu and Alvarez-Buylla, 2002) . The turnover mode of neurons with replacement of about 10% by newly arriving neurons has been most clearly established in the dentate gyrus (Lagace et al., 2007; Ninkovic et al., 2007) and implies a rather specific regulation of neuronal survival. Notably, the mode of neuron incorporation in the glomerular layer (GL) is very different. Long-term fate mapping of adult generated neurons has revealed a constant increase in their proportion in the GL (Ninkovic et al., 2007) , suggesting the addition of new neurons to this network rather than a replacement of preexisting neurons.
Our data now demonstrate mature neurons in the GL require the direct transcriptional orchestration of a survival pathway. We showed that CryaA is expressed in the brain in a highly region-specific manner and acts as an essential survival factor in dopaminergic OB interneurons in the adult mouse brain (Figure 3 ). CryaA prevents procaspase-3 activation possibly by interaction with Bax and Bcl-Xl as demonstrated in the lens (Mao et al., 2004) or by physical interaction and inhibition of its autocatalytic activation (Kamradt et al., 2001 ). Moreover, crystallins, as molecular chaperons, interact with the cytoskeleton (Bai et al., 2007) and prevent the deposition of protein aggregates (Bai et al., 2007; Narayanan et al., 2006; Rekas et al., 2004) thereby promoting cell survival (Andley, 2007) in a caspase-independent manner. However, our data are not consistent with the latter mechanisms of CryaA function since cell death by aggregation of proteins would be expected to occur at a slower pace than observed after shRNA-mediated knockdown and the loss of Pax6 and CryaA in the Pax6 mutant OBs. Moreover, our in vitro experiments also support a direct role of CryaA in the regulation of cell survival by influencing procaspase-3 activation. It has been previously shown that deletion of CryaA leads to a decrease in Bad S136 phosphorylation, a potent signal for apoptosis (Xi et al., 2008) . In addition, CryaA also interacts with p53 and hence its loss may affect cell death at various levels (Andley, 2007) .
One of the most important aspects of this work is the specificity of this pathway affecting exclusively dopaminergic OB interneurons. Knockdown of CryaA in other adult generated neurons did not affect their survival. This is particularly relevant in regard to the alterations of dopaminergic OB interneuron numbers which have been observed in Parkinson's disease patients (Hirsch et al., 1987; Shih et al., 2007; Sulzer, 2007) . Interestingly, P19 cells that also depend on CryaA for suppression of caspase-3-dependent cell death are also both GABAergic and dopaminergic (Staines et al., 1994) and express Pax6 as well as CryaA. It may thus be that CryaA is involved in a specific survival pathway active in OB dopaminergic neurons. While we did not observe CryaA expression in midbrain dopaminergic neurons, different members of the crystallin family are expressed in different brain regions and may be implicated in regulating neuronal survival (Ganguly et al., 2008; Magabo et al., 2000; Renkawek et al., 1992) . Other homeobox transcription factors could regulate crystallins in other neuronal subtypes, such that this survival pathway may play a general role in specific neurons of the adult brain. The finding that neuronal survival in a healthy adult brain is regulated in a subtype-specific manner is therefore highly relevant to the subtype-specific vulnerability of neurons in many neurodegenerative diseases.
Pax6 Exerts Different Functions via Distinct DNA-Binding Domains
The survival pathway in dopaminergic OB neurons is mediated by the same TF specifying these neurons, but utilizes a different DNA-binding domain, namely the homeodomain. Interestingly, the regulation of CryaA via the HD in the brain is not semidominant as PD-regulated effects of proliferation, neurogenesis, and patterning during development (Ellison-Wright et al., 2004; Estivill-Torrus et al., 2002; Gö tz et al., 1998; Heins et al., 2002; Kroll and O'Leary, 2005; Stoykova et al., 2000; Toresson et al., 2000; Yun et al., 2001) . This is rather different in eye development, where mutations of the HD exhibit strong and early phenotypes (Favor et al., 2001 . Notably, the regulation of crystallins is mediated by the PD in the eye and in lens cells (Chauhan et al., 2002; Cvekl and Duncan, 2007; Cvekl et al., 1994; Wolf et al., 2009 ), while we show here that it requires the interaction with a full-length and a PDless Pax6 to mediate HD-dependent target regulation.
Lack of Pax6 function can also result in cell death in the developing forebrain (Nikoletopoulou et al., 2007) . Interestingly, this cell death is mediated by p75 and occurs as a consequence of misspecification as the misspecified Pax6 mutant GABAergic neurons survive well in other brain regions where GABAergic neurons are normally generated (Nikoletopoulou et al., 2007) . In the normal case Pax6-positive progenitors give rise to glutamatergic neurons (Kroll and O'Leary, 2005; Nikoletopoulou et al., 2007; Stoykova et al., 2000) . In the absence of Pax6, upregulation of the transcription factors Gsh2, Mash1, and Dlx2 occurs and results in the generation of GABAergic neurons (Kroll and O'Leary, 2005; Schuurmans and Guillemot, 2002; Stoykova et al., 2000; Toresson et al., 2000) . When the transient wave of early cell death is rescued by p75 depletion, the misspecified GABAergic neurons survive (Nikoletopoulou et al., 2007) . Conversely, rescue of Pax6-deficient dopaminergic OB neurons resulted in the survival of dopaminergic and not other misspecified neuronal subtype. Pax6 expression is transient in the stem and progenitor cells of the developing cerebral cortex and it does not continue in the differentiating glutamatergic neurons in this region (Gö tz et al., 1998) . This further highlights that the cell death of misspecified neurons in the developing cortex is not a direct cause of absence of Pax6 function but depends on the local environment and neuronal misspecification. Conversely, Pax6 exerts a primary role in the regulation of neuronal survival in adult neurons, where it is continuously expressed, by direct regulation of the survival component CryaA that inhibits the apoptosis pathway. Taken together, Pax6 changes its role from PD-mediated transcriptional regulation specifying fate in progenitor cells to HD-mediated transcriptional regulation of cell survival in mature neurons. 
Histology and Immunostaining
Immunostainings and analyses were performed as previously described (Brill et al., 2008 In Situ Hybridization Digoxigenin-labeled RNA probes for CryaA, CryaB, CrybB2, and Cryg (kindly provided by J. Graw) were made and used as described previously (Brill et al., 2008) .
Western Blot Specific brain areas were dissected and lysed in RIPA buffer containing protease and phosphatase inhibitors (Roche). Ten micrograms of total proteins were separated by 10% SDS-PAGE and transferred to PVDF membranes (Bio-Rad). Membranes were incubated with primary antibodies followed by horseradish peroxidase labeled secondary antibodies (1:25 000; Amersham). These were detected by ECL Western Blotting Detection (Chemicon). The abundance of the band was quantified using ImageJ software after background correction.
Immunoprecipitations
Nuclear extracts were prepared from freshly dissected OBs and dialyzed to 100 mM KCl as described previously (Dignam et al., 1983) . For the immunoprecipitation, 10 mg of anti-Pax6 antibody (Hybridoma Developmental Bank) was used for 300 ml of OB nuclear extract
FACS Analysis for Cell Death and Neuroblasts
Olfactory bulbs were dissected and dissociated to single-cell suspension as previously described (Brill et al., 2008) . Single-cell suspensions were assessed for cell death using PI/annexinV kit (eBioscience) and FACS analysis according to the manufacturers' recommendations. To assess number of neuroblasts, cells were labeled with mouse anti/PSA-NCAM antibody (Chemicon, 1: 500) for 15 min on ice, followed with Cy-5 conjugated secondary antibody and FACS analyses.
Luciferase Assay
Expression plasmids for luciferase reporter assays were constructed using full-length cDNA of mouse Sox2, Pax6, Pax6(5a), and PDless cloned into the pMXIG vector. The empty vector was used as control. The 2.1 kb CryaA promoter was cloned into the pGL3 vector (Promega). The CryaA promoter was PCR amplified from genomic DNA using the following primers: 5 0 -TTTATGTATATGAGTACGCTGTTGC and 5 0 -TCTATTTGGTGATGCAGGGA.
We used mouse neuroblastoma (Neuro-2A) and mouse embryonic carcinoma P19 cells (0.5 3 10 5 cells/ cm 2 ) and assays we performed according to the manufacturer's instructions (Promega).
Viral Constructs, Virus Production, and Stereotactic Injections
Full-length cDNA of mouse CryaA was cloned into CAG-RFP retroviral vector (cytomegalovirus immediate-early enhancer-chicken b-actin hybrid-red fluorescent protein). An empty CAG-dsRed vector was used as a control.
Retrovirus was produced in a packaging cell line (GPG-293) after transient transfection with the retroviral expression plasmid. Estimation of the viral titer was performed as described (Hack et al., 2005) and titered to 5 3 10 7 colony-forming units (cfu) ml À1 . For all experiments, 10-week-old males were stereotactically injected with 1 ml of either CAG-DsRed, CAG-CryaA-DsRed, or shRNA lentiviruses into the left and the right RMS (coordinates relative to the bregma were (in mm): À2.8 anterior/posterior, 0.75 medial/lateral, and À1.9 dorsal/ventral from the dura).
Short-Hairpin RNAs
The short-hairpin RNAs (shRNAs) were designed using BLOCK-iT RNAi Designer (Invitrogen) against the full-length cDNA of CryaA and contain sense, four nucleotides CGAA as the loop, antisense sequences and two adapters for the BglII and HindIII sites. The synthesized double-stranded DNA nucleotides were annealed and ligated into pLVTH plasmids (Wiznerowicz and Trono, 2003) after the H1 promoter. Oligonucleotides designed for CryaA were CryaA_shRNA5: GACTGTTCGACCAGTTCTTCG (21 bp) and CryaA_shRNA6: GTCACCATTCAGCATCCTTGG (21 bp) and nonspecific shRNA: GGTTTGGCA TATAATCTATCG (21 bp). P19 cells were transiently transfected with the shRNA encoding plasmids using Lipofectamine2000 (Invitrogen) according to the manufacturers' specifications and assayed for either cell death or immunocytochemistry as described above.
Chromatin Immunoprecipitation (ChIP) Assays
The qChIP experiments were performed as described (Cuddapah et al., 2009; Lee et al., 2006) with minor modifications. The detailed protocol is available in supplemental material. We used rabbit anti-Pax6 (Millipore/Chemicon, cat # ab2237) or H3K9ac polyclonal antibodies (Abcam, cat #ab4441) for IP. 
